Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2025PharmaceuticsOpen Access

Formulation and Comparative Characterization of SLNs and NLCs for Targeted Co-Delivery of Paclitaxel and Hydroxytyrosol Carboxylic Acid Esters Against Triple-Negative Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

EPElena PeiraSSSimona SapinoDCDaniela Chirio

Discussion

Loading...

Member takes

Overview

This study demonstrates that SLNs and NLCs enhance drug delivery in triple-negative breast cancer, indicating potential to overcome multidrug resistance.

Key Points

  • SLNs of trilaurin exhibited enhanced entrapment efficiency and stability, improving drug delivery in TNBC.
  • Cytotoxicity assays show PTX-loaded TL-SLNs significantly enhance antitumor activity, especially when co-administered with hydroxytyrosol.
  • Hyaluronic acid decoration increases particle size and targeting potential through HA-CD44 interaction, reflecting improved delivery strategy.
  • Cn-HTyrCA derivatives showed superior loading capacity, suggesting their role in addressing hypoxia-related resistance mechanisms.

Cite This Study

Peira et al. (2025) studied this question.

synapsesocial.com/papers/68d45b1b31b076d99fa5d6ffhttps://doi.org/10.3390/pharmaceutics17091208
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Integrin αvβ3–Targeted SLNs for Co-Delivery of Paclitaxel and Quercetin in Triple-Negative Breast Cancer2026 · 1 citations
  2. 2Hyaluronic Acid‐Decorated Hollow Nanocapsules for Enhanced Tumor‐Targeted Chemotherapy2026
  3. 3Targeted lipid-polymer hybrid nanocapsules for controlled codelivery of doxorubicin and paclitaxel: physicochemical characterization and In vitro anticancer evaluation.2026
  4. 4Tamoxifen loaded lipid nanoparticles as a novel therapeutic approach enhancing apoptotic cell death in triple negative breast cancer cells2026 · 1 citations
  5. 5Potentiating Paclitaxel with its Homologous Nanovesicles: A Synergistic Strategy for Triple-Negative Breast Cancer Therapy2026